Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 02
2024
|
Sheila A. Denton EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,136
-6.58%
|
$143,112
$67.63 P/Share
|
|
Oct 01
2024
|
Lee Heeson EVP, Head of Incyte Intl |
BUY
Grant, award, or other acquisition
|
Direct |
26,447
+50.0%
|
-
|
|
Sep 30
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
992
+0.01%
|
-
|
|
Sep 30
2024
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
378
+2.21%
|
$24,948
$66.1 P/Share
|
|
Sep 30
2024
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
368
+1.86%
|
$24,288
$66.1 P/Share
|
|
Sep 13
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
382
-1.54%
|
$24,066
$63.37 P/Share
|
|
Sep 12
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
572
-2.25%
|
$35,464
$62.94 P/Share
|
|
Sep 12
2024
|
Jonathan Elliott Dickinson EVP, General Manager, Europe |
SELL
Open market or private sale
|
Direct |
8,450
-9.63%
|
$523,900
$62.33 P/Share
|
|
Aug 12
2024
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,608
-11.42%
|
$696,480
$60.63 P/Share
|
|
Jul 25
2024
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
15,571
-29.79%
|
$1,089,970
$70.0 P/Share
|
|
Jul 16
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
1,306
-2.2%
|
$83,584
$64.19 P/Share
|
|
Jul 15
2024
|
Paula J Swain EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
549
-0.63%
|
$35,136
$64.25 P/Share
|
|
Jul 15
2024
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
7,278
+7.75%
|
-
|
|
Jul 15
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
466
-1.8%
|
$29,824
$64.25 P/Share
|
|
Jul 15
2024
|
Thomas Tray Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,073
+16.4%
|
-
|
|
Jul 15
2024
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,555
-1.51%
|
$99,520
$64.25 P/Share
|
|
Jul 15
2024
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,895
+11.87%
|
-
|
|
Jul 15
2024
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
948
-0.99%
|
$60,672
$64.25 P/Share
|
|
Jul 15
2024
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,572
+11.56%
|
-
|
|
Jul 15
2024
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Payment of exercise price or tax liability
|
Direct |
549
-1.04%
|
$35,136
$64.25 P/Share
|
|
Jul 15
2024
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
7,278
+12.11%
|
-
|
|
Jul 15
2024
|
Herve Hoppenot Chairman / CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,961
-0.99%
|
$317,504
$64.25 P/Share
|
|
Jul 15
2024
|
Herve Hoppenot Chairman / CEO |
BUY
Grant, award, or other acquisition
|
Direct |
41,025
+7.56%
|
-
|
|
Jul 15
2024
|
Pablo J Cagnoni President, R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
749
-0.34%
|
$47,936
$64.25 P/Share
|
|
Jul 15
2024
|
Pablo J Cagnoni President, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
19,851
+8.21%
|
-
|
|
Jul 15
2024
|
Matteo Trotta EVP, GM, Dermatology US |
BUY
Grant, award, or other acquisition
|
Direct |
2,646
+20.17%
|
-
|
|
Jul 15
2024
|
Sheila A. Denton EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,955
+15.49%
|
-
|
|
Jul 15
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
1,111
-1.84%
|
$71,104
$64.25 P/Share
|
|
Jul 15
2024
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
9,925
+14.1%
|
-
|
|
Jul 09
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
8,148
-13.89%
|
$488,880
$60.0 P/Share
|
|
Jul 02
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
7,695
-11.59%
|
$454,005
$59.02 P/Share
|
|
Jul 02
2024
|
Herve Hoppenot Chairman / CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
41,723
-8.31%
|
$2,461,657
$59.02 P/Share
|
|
Jul 02
2024
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
844
-3.9%
|
$49,796
$59.02 P/Share
|
|
Jul 02
2024
|
Paula J Swain EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
5,560
-6.55%
|
$328,040
$59.02 P/Share
|
|
Jul 02
2024
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,316
-8.52%
|
$490,644
$59.02 P/Share
|
|
Jul 02
2024
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,870
-7.6%
|
$405,330
$59.02 P/Share
|
|
Jul 02
2024
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Payment of exercise price or tax liability
|
Direct |
5,706
-11.13%
|
$336,654
$59.02 P/Share
|
|
Jun 28
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
1,074
+0.01%
|
-
|
|
Jun 28
2024
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
409
+2.44%
|
$24,540
$60.62 P/Share
|
|
Jun 28
2024
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
399
+2.06%
|
$23,940
$60.62 P/Share
|
|
Jun 12
2024
|
Baker Bros. Advisors LP |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,459,183
-10.84%
|
$327,550,980
$60.0 P/Share
|
|
Jun 12
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
5,660
+0.05%
|
-
|
|
Jun 12
2024
|
Susanne Schaffert Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+33.1%
|
-
|
|
Jun 12
2024
|
Susanne Schaffert Director |
SELL
Payment of exercise price or tax liability
|
Direct |
752
-20.65%
|
$44,368
$59.94 P/Share
|
|
Jun 12
2024
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+24.47%
|
-
|
|
Jun 12
2024
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+20.73%
|
-
|
|
Jun 12
2024
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+14.41%
|
-
|
|
Jun 12
2024
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+13.38%
|
-
|
|
Jun 12
2024
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
19,164
-22.4%
|
$1,149,840
$60.0 P/Share
|
|
Jun 12
2024
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,830
+13.2%
|
-
|